Gene · 3702
ITK: IL2 inducible T cell kinase
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ITK: IL2 inducible T cell kinase. Genes, record 3702. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3702
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q08881 | Tyrosine-protein kinase ITK/TSK | 620 | 37 | Ensembl, GeneID, HGNC |
Source UniProt
Patents88
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 49624 | Q08881 | Espacenet |
| EP 4661970 A1 | 2025-12-17 | 62154 | Q08881 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 14476 | Q08881 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 14476 | Q08881 | Espacenet |
| US 12006548 B2 | 2024-06-11 | 395 | Q08881 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 39528 | Q08881 | Espacenet |
| US 11351168 B1 | 2022-06-07 | 3 | Q08881 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 142499 | Q08881 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 5638 | Q08881 | Espacenet |
| US 11015221 B2 | 2021-05-25 | 100 | Q08881 | Espacenet |
1 to 10 of 88
See all 88 patentsDrugs4
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| PAZOPANIB | CHEMBL477772 | Tyrosine-protein kinase ITK/TSK inhibitor | INHIBITOR | ChEMBL |
| PAZOPANIB HYDROCHLORIDE | CHEMBL1201733 | Tyrosine-protein kinase ITK/TSK inhibitor | INHIBITOR | ChEMBL |
| RITLECITINIB | CHEMBL4085457 | TEC family kinase inhibitor | INHIBITOR | ChEMBL |
| RITLECITINIB TOSYLATE | CHEMBL5314649 | TEC family kinase inhibitor | INHIBITOR | ChEMBL |
Trials235
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07444619 | PAZOPANIB | PHASE1 | ClinicalTrials.gov | |
| NCT07228390 | RITLECITINIB | PHASE2 | ClinicalTrials.gov | |
| NCT07226531 | RITLECITINIB | ClinicalTrials.gov | ||
| NCT07200128 | RITLECITINIB | ClinicalTrials.gov | ||
| NCT07152626 | RITLECITINIB | PHASE2 | ClinicalTrials.gov | |
| NCT07152119 | RITLECITINIB TOSYLATE | ClinicalTrials.gov | ||
| NCT07087158 | PAZOPANIB | PHASE2 | ClinicalTrials.gov | |
| NCT07029828 | RITLECITINIB | PHASE3 | ClinicalTrials.gov | |
| NCT07029711 | RITLECITINIB | PHASE3 | ClinicalTrials.gov | |
| NCT06873945 | RITLECITINIB | PHASE3 | ClinicalTrials.gov |
1 to 10 of 235
See all 235 trialsNIH grants1,876
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ITK papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 39 | 2025 |
| R01AI043957 | Structural Studies of a T cell Specific Tyrosine Kinase | 35 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 24 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 16 | 2025 |
| P01AI091580 | Defining the Unique Properties of the Distinct Signaling Machinery Used by the TCR | 11 | 2025 |
| UL1TR001866 | Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational Success | 9 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 8 | 2025 |
| R01CA177292 | Targeted Therapies for Lymphoid Malignancies | 8 | 2025 |
| ZIAHL002346 | Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy | 8 | 2025 |
| ZIABC010304 | Biochemical Basis of T Cell Activation | 6 | 2025 |
1 to 10 of 1,876Source NIH's project files
See all 1,876 nih grantsPapers2,789
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Corrigendum to "Purification and characterization of full-length monomeric TEC family kinase, ITK" [Protein Expr. Purif. 229 (2025) 106682]. | Protein Expr Purif | 2027 | 42575776 | PubTator, text mining | PubMed |
| Mechanism and Individualized Management of Hypertension Associated With Bruton Tyrosine Kinase Inhibitors: The PCSK9/Notch3 Signaling Pathway. | Front Biosci (Landmark Ed) | 2026 | 42811994 | PubTator, text mining | PubMed |
| A multi-omics integrative analyses reveals CYBB-mediated apoptotic and immune dysregulation as a key target of berberine in diffuse large B-cell lymphoma. | Front Pharmacol | 2026 | 42730162 | PubTator, text mining | PubMed |
| Spectrum of Primary Hemophagocytic Lymphohistiocytosis-Associated Gene Mutations in Chinese Patients. | MedComm (2020) | 2026 | 42688879 | PubTator, text mining | PubMed |
| C-terminal CD28 phosphorylation, pY218, modulates IL-2 secretion and therapeutic effect of CAR-T cells. | Mol Ther | 2026 | 42642932 | PubTator, text mining | PubMed |
| Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas. | Blood | 2026 | 42640855 | PubTator, text mining | PubMed |
| Design, synthesis, and biological evaluation of novel 4-aminoquinoline benzoyl hydrazine derivatives as noncovalent BTK inhibitors for hematologic malignancies. | Eur J Med Chem | 2026 | 42566884 | PubTator, text mining | PubMed |
| Randomized phase 2a study of TAS5315, a Bruton's tyrosine kinase inhibitor, for chronic spontaneous urticaria. | Allergol Int | 2026 | 42448553 | PubTator, text mining | PubMed |
| Riding toward Selectivity: Optimization of Covalent 7-Azaindole-Based BMX Kinase Inhibitors. | J Med Chem | 2026 | 42441922 | PubTator, text mining | PubMed |
| Inhibition of the ZEB1-BCL2 axis in cancer-associated fibroblasts as a strategy to improve chemotherapy response in intrahepatic cholangiocarcinoma. | Biomed Pharmacother | 2026 | 42407325 | PubTator, text mining | PubMed |
1 to 10 of 2,789
See all 2,789 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3702
GET https://conductscience.org/api/genes/v1/3702/patents?page=2